nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Lomustine—hematologic cancer	0.0681	0.189	CbGbCtD
Methylphenidate—CYP2D6—Idarubicin—hematologic cancer	0.0607	0.168	CbGbCtD
Methylphenidate—CYP2D6—Hydroxyurea—hematologic cancer	0.0516	0.143	CbGbCtD
Methylphenidate—CYP2D6—Bortezomib—hematologic cancer	0.0449	0.124	CbGbCtD
Methylphenidate—CYP2D6—Imatinib—hematologic cancer	0.0329	0.0912	CbGbCtD
Methylphenidate—CYP2D6—Nilotinib—hematologic cancer	0.0299	0.0829	CbGbCtD
Methylphenidate—CYP2D6—Vinorelbine—hematologic cancer	0.0296	0.0822	CbGbCtD
Methylphenidate—CYP2D6—Vinblastine—hematologic cancer	0.0183	0.0506	CbGbCtD
Methylphenidate—CYP2D6—Dexamethasone—hematologic cancer	0.0135	0.0375	CbGbCtD
Methylphenidate—CYP2D6—Doxorubicin—hematologic cancer	0.0112	0.0311	CbGbCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.000576	0.0115	CbGpPWpGaD
Methylphenidate—SLC6A4—Serotonin Transporter Activity—IL1B—hematologic cancer	0.000565	0.0113	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—PER1—hematologic cancer	0.000556	0.0111	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—LCK—hematologic cancer	0.000532	0.0107	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PER3—hematologic cancer	0.000514	0.0103	CbGpPWpGaD
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	0.000511	0.0102	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.000455	0.00912	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP7—hematologic cancer	0.000446	0.00892	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SYK—hematologic cancer	0.000439	0.0088	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PER2—hematologic cancer	0.000437	0.00875	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CRY2—hematologic cancer	0.000437	0.00875	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CRY1—hematologic cancer	0.000437	0.00875	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.00042	0.00841	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—ARNTL—hematologic cancer	0.000396	0.00794	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—TSC2—hematologic cancer	0.000385	0.00772	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CYCS—hematologic cancer	0.000376	0.00753	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—ID3—hematologic cancer	0.000372	0.00744	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—RET—hematologic cancer	0.000371	0.00743	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—MAPK14—hematologic cancer	0.000367	0.00735	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TSC2—hematologic cancer	0.000331	0.00664	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PER1—hematologic cancer	0.000331	0.00663	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—KMT2A—hematologic cancer	0.000331	0.00663	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—MAPK14—hematologic cancer	0.000316	0.00632	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TOP1—hematologic cancer	0.000303	0.00607	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—hematologic cancer	0.000301	0.00602	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—ID2—hematologic cancer	0.000295	0.00591	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TSC2—hematologic cancer	0.000294	0.00588	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—MAPK14—hematologic cancer	0.00028	0.0056	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—ABCC3—hematologic cancer	0.000276	0.00552	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TXN—hematologic cancer	0.000276	0.00552	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—BAD—hematologic cancer	0.000275	0.0055	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—hematologic cancer	0.000266	0.00533	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000261	0.00524	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—UGT1A1—hematologic cancer	0.000259	0.00519	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.000253	0.00507	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.000251	0.00502	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—MAPK14—hematologic cancer	0.000244	0.00488	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000241	0.00483	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—IL1B—hematologic cancer	0.00024	0.00482	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TXN—hematologic cancer	0.000237	0.00475	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—ABCC3—hematologic cancer	0.000237	0.00475	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—ARNTL—hematologic cancer	0.000236	0.00473	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000232	0.00464	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—UGT1A1—hematologic cancer	0.000223	0.00446	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—ABCC3—hematologic cancer	0.00021	0.00421	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TXN—hematologic cancer	0.00021	0.00421	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—IL1B—hematologic cancer	0.000207	0.00414	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000207	0.00414	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.000206	0.00413	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000205	0.00411	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUND—hematologic cancer	0.000201	0.00402	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—UGT1A1—hematologic cancer	0.000197	0.00395	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000186	0.00373	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—IL1B—hematologic cancer	0.000183	0.00367	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000183	0.00367	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CST3—hematologic cancer	0.00018	0.00361	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—NQO1—hematologic cancer	0.000178	0.00356	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—hematologic cancer	0.000175	0.0035	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—FOXO1—hematologic cancer	0.000173	0.00345	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PML—hematologic cancer	0.00017	0.0034	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000167	0.00335	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HSP90AA1—hematologic cancer	0.000167	0.00334	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SRC—hematologic cancer	0.000163	0.00327	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—STAT3—hematologic cancer	0.000162	0.00324	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—hematologic cancer	0.000159	0.00319	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000155	0.00311	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TOP2A—hematologic cancer	0.000155	0.00311	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—NQO1—hematologic cancer	0.000153	0.00306	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—hematologic cancer	0.00015	0.00301	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—TGFB1—hematologic cancer	0.00015	0.003	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000149	0.00299	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—hematologic cancer	0.000148	0.00297	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000148	0.00297	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000148	0.00296	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—EZH2—hematologic cancer	0.000147	0.00295	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HSP90AA1—hematologic cancer	0.000144	0.00288	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—HDAC2—hematologic cancer	0.000139	0.00279	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000138	0.00276	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000137	0.00274	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000137	0.00274	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HGF—hematologic cancer	0.000136	0.00273	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM1—hematologic cancer	0.000136	0.00273	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—NQO1—hematologic cancer	0.000135	0.00271	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—SLC35B2—hematologic cancer	0.000134	0.00268	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—hematologic cancer	0.000133	0.00266	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—EPHX1—hematologic cancer	0.000132	0.00264	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.00013	0.0026	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000129	0.00259	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000129	0.00258	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—hematologic cancer	0.000127	0.00255	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HSP90AA1—hematologic cancer	0.000127	0.00255	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000127	0.00254	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000124	0.00249	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000122	0.00244	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000121	0.00242	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000119	0.00239	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000118	0.00236	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—PDGFB—hematologic cancer	0.000117	0.00235	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HGF—hematologic cancer	0.000117	0.00234	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—hematologic cancer	0.000117	0.00234	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC22A1—hematologic cancer	0.000114	0.00229	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000114	0.00229	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—hematologic cancer	0.000113	0.00226	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000112	0.00225	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000111	0.00222	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.00011	0.00221	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NCOR1—hematologic cancer	0.000105	0.00211	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000105	0.0021	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ADCY7—hematologic cancer	0.000105	0.0021	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000104	0.00209	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HGF—hematologic cancer	0.000104	0.00208	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—hematologic cancer	0.000104	0.00208	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—PDGFB—hematologic cancer	0.000101	0.00202	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PRKCG—hematologic cancer	0.000101	0.00201	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	9.81e-05	0.00197	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SGK1—hematologic cancer	9.6e-05	0.00192	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	9.6e-05	0.00192	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	9.6e-05	0.00192	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—FAS—hematologic cancer	9.45e-05	0.00189	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CAMK2D—hematologic cancer	9.33e-05	0.00187	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	9.3e-05	0.00186	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREB1—hematologic cancer	9.13e-05	0.00183	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—PDGFB—hematologic cancer	8.92e-05	0.00179	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6R—hematologic cancer	8.9e-05	0.00178	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	8.89e-05	0.00178	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	8.65e-05	0.00173	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTO1—hematologic cancer	8.63e-05	0.00173	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTO1—hematologic cancer	8.51e-05	0.0017	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP4A—hematologic cancer	8.51e-05	0.0017	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ANXA2—hematologic cancer	8.51e-05	0.0017	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SGK1—hematologic cancer	8.51e-05	0.0017	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CDK4—hematologic cancer	8.32e-05	0.00167	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—UGT1A1—hematologic cancer	8.11e-05	0.00162	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—UGT1A1—hematologic cancer	8e-05	0.0016	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PRKCG—hematologic cancer	7.69e-05	0.00154	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	7.66e-05	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	7.59e-05	0.00152	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CREB1—hematologic cancer	7.45e-05	0.00149	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—MTR—hematologic cancer	7.03e-05	0.00141	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	6.94e-05	0.00139	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL1B—hematologic cancer	6.77e-05	0.00136	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—hematologic cancer	6.76e-05	0.00135	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC3—hematologic cancer	6.72e-05	0.00135	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—hematologic cancer	6.69e-05	0.00134	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—JUN—hematologic cancer	6.56e-05	0.00131	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—NUP98—hematologic cancer	6.55e-05	0.00131	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	6.36e-05	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—NUP214—hematologic cancer	6.32e-05	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	6.19e-05	0.00124	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	6.15e-05	0.00123	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—EP300—hematologic cancer	6.05e-05	0.00121	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PRKCG—hematologic cancer	5.9e-05	0.00118	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—NUP98—hematologic cancer	5.81e-05	0.00116	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	5.73e-05	0.00115	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CREB1—hematologic cancer	5.7e-05	0.00114	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ADCY7—hematologic cancer	5.64e-05	0.00113	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BRAF—hematologic cancer	5.63e-05	0.00113	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—NUP214—hematologic cancer	5.6e-05	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFB1—hematologic cancer	5.55e-05	0.00111	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TFRC—hematologic cancer	5.52e-05	0.0011	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCG2—hematologic cancer	5.48e-05	0.0011	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUN—hematologic cancer	5.36e-05	0.00107	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—hematologic cancer	5.18e-05	0.00104	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—MAPK8—hematologic cancer	5.07e-05	0.00102	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—EP300—hematologic cancer	4.94e-05	0.00099	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—hematologic cancer	4.91e-05	0.000984	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TFRC—hematologic cancer	4.89e-05	0.000979	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFB1—hematologic cancer	4.77e-05	0.000956	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—ALB—hematologic cancer	4.75e-05	0.000952	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MDM2—hematologic cancer	4.71e-05	0.000944	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—hematologic cancer	4.64e-05	0.000929	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.63e-05	0.000927	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—hematologic cancer	4.57e-05	0.000916	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CREB1—hematologic cancer	4.37e-05	0.000874	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BRAF—hematologic cancer	4.31e-05	0.000864	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—hematologic cancer	4.26e-05	0.000853	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFB1—hematologic cancer	4.23e-05	0.000847	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—ALB—hematologic cancer	4.21e-05	0.000844	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—hematologic cancer	4.2e-05	0.000842	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.1e-05	0.000821	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—hematologic cancer	3.97e-05	0.000794	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.86e-05	0.000774	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—MDM2—hematologic cancer	3.61e-05	0.000724	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GMPS—hematologic cancer	3.55e-05	0.000712	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—FTCD—hematologic cancer	3.55e-05	0.000712	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PHYH—hematologic cancer	3.55e-05	0.000712	CbGpPWpGaD
Methylphenidate—Eye disorder—Doxorubicin—hematologic cancer	3.54e-05	6e-05	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—hematologic cancer	3.54e-05	0.000708	CbGpPWpGaD
Methylphenidate—Ill-defined disorder—Methotrexate—hematologic cancer	3.53e-05	5.99e-05	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—hematologic cancer	3.52e-05	5.97e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Dexamethasone—hematologic cancer	3.52e-05	5.97e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Betamethasone—hematologic cancer	3.52e-05	5.97e-05	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—hematologic cancer	3.51e-05	5.96e-05	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—hematologic cancer	3.51e-05	5.96e-05	CcSEcCtD
Methylphenidate—Tension—Epirubicin—hematologic cancer	3.5e-05	5.93e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Betamethasone—hematologic cancer	3.49e-05	5.92e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.49e-05	5.92e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Triamcinolone—hematologic cancer	3.47e-05	5.88e-05	CcSEcCtD
Methylphenidate—Nervousness—Epirubicin—hematologic cancer	3.46e-05	5.87e-05	CcSEcCtD
Methylphenidate—Back pain—Epirubicin—hematologic cancer	3.45e-05	5.85e-05	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—hematologic cancer	3.43e-05	5.83e-05	CcSEcCtD
Methylphenidate—Malaise—Methotrexate—hematologic cancer	3.43e-05	5.83e-05	CcSEcCtD
Methylphenidate—Dizziness—Etoposide—hematologic cancer	3.43e-05	5.82e-05	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—hematologic cancer	3.42e-05	5.81e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.42e-05	0.000685	CbGpPWpGaD
Methylphenidate—Immune system disorder—Doxorubicin—hematologic cancer	3.42e-05	5.8e-05	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—hematologic cancer	3.42e-05	5.8e-05	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—hematologic cancer	3.41e-05	5.79e-05	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—hematologic cancer	3.41e-05	5.78e-05	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—hematologic cancer	3.4e-05	5.77e-05	CcSEcCtD
Methylphenidate—Urticaria—Dexamethasone—hematologic cancer	3.39e-05	5.75e-05	CcSEcCtD
Methylphenidate—Urticaria—Betamethasone—hematologic cancer	3.39e-05	5.75e-05	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.39e-05	5.75e-05	CcSEcCtD
Methylphenidate—Dizziness—Prednisolone—hematologic cancer	3.38e-05	5.74e-05	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—hematologic cancer	3.38e-05	5.74e-05	CcSEcCtD
Methylphenidate—Asthenia—Triamcinolone—hematologic cancer	3.37e-05	5.73e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Betamethasone—hematologic cancer	3.37e-05	5.73e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Dexamethasone—hematologic cancer	3.37e-05	5.73e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Dexamethasone—hematologic cancer	3.37e-05	5.73e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Betamethasone—hematologic cancer	3.37e-05	5.73e-05	CcSEcCtD
Methylphenidate—Nausea—Cisplatin—hematologic cancer	3.36e-05	5.71e-05	CcSEcCtD
Methylphenidate—Insomnia—Prednisone—hematologic cancer	3.36e-05	5.71e-05	CcSEcCtD
Methylphenidate—Vision blurred—Epirubicin—hematologic cancer	3.36e-05	5.7e-05	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—hematologic cancer	3.35e-05	5.68e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Prednisone—hematologic cancer	3.34e-05	5.66e-05	CcSEcCtD
Methylphenidate—Pruritus—Triamcinolone—hematologic cancer	3.33e-05	5.65e-05	CcSEcCtD
Methylphenidate—Cough—Methotrexate—hematologic cancer	3.32e-05	5.64e-05	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—hematologic cancer	3.32e-05	5.63e-05	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—hematologic cancer	3.3e-05	5.61e-05	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—hematologic cancer	3.3e-05	5.6e-05	CcSEcCtD
Methylphenidate—Vomiting—Etoposide—hematologic cancer	3.3e-05	5.6e-05	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—hematologic cancer	3.3e-05	5.59e-05	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—hematologic cancer	3.3e-05	5.59e-05	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—hematologic cancer	3.29e-05	5.59e-05	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—hematologic cancer	3.27e-05	5.56e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Prednisone—hematologic cancer	3.27e-05	5.55e-05	CcSEcCtD
Methylphenidate—Rash—Etoposide—hematologic cancer	3.27e-05	5.55e-05	CcSEcCtD
Methylphenidate—Dermatitis—Etoposide—hematologic cancer	3.27e-05	5.54e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—SMPD3—hematologic cancer	3.25e-05	0.000651	CbGpPWpGaD
Methylphenidate—Headache—Etoposide—hematologic cancer	3.25e-05	5.51e-05	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—hematologic cancer	3.24e-05	5.5e-05	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—hematologic cancer	3.24e-05	5.5e-05	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—hematologic cancer	3.24e-05	5.5e-05	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—hematologic cancer	3.24e-05	0.000648	CbGpPWpGaD
Methylphenidate—Tension—Doxorubicin—hematologic cancer	3.23e-05	5.49e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Prednisone—hematologic cancer	3.23e-05	5.48e-05	CcSEcCtD
Methylphenidate—Rash—Prednisolone—hematologic cancer	3.23e-05	5.47e-05	CcSEcCtD
Methylphenidate—Dermatitis—Prednisolone—hematologic cancer	3.22e-05	5.47e-05	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.22e-05	5.46e-05	CcSEcCtD
Methylphenidate—Malaise—Epirubicin—hematologic cancer	3.21e-05	5.45e-05	CcSEcCtD
Methylphenidate—Fatigue—Prednisone—hematologic cancer	3.2e-05	5.44e-05	CcSEcCtD
Methylphenidate—Headache—Prednisolone—hematologic cancer	3.2e-05	5.44e-05	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—hematologic cancer	3.2e-05	5.43e-05	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—hematologic cancer	3.2e-05	5.43e-05	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—hematologic cancer	3.2e-05	5.43e-05	CcSEcCtD
Methylphenidate—Syncope—Epirubicin—hematologic cancer	3.19e-05	5.42e-05	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—hematologic cancer	3.19e-05	5.41e-05	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—hematologic cancer	3.19e-05	5.41e-05	CcSEcCtD
Methylphenidate—Constipation—Prednisone—hematologic cancer	3.18e-05	5.39e-05	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—hematologic cancer	3.17e-05	5.38e-05	CcSEcCtD
Methylphenidate—Palpitations—Epirubicin—hematologic cancer	3.15e-05	5.34e-05	CcSEcCtD
Methylphenidate—Confusional state—Methotrexate—hematologic cancer	3.13e-05	5.32e-05	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—hematologic cancer	3.13e-05	5.31e-05	CcSEcCtD
Methylphenidate—Dizziness—Triamcinolone—hematologic cancer	3.11e-05	5.28e-05	CcSEcCtD
Methylphenidate—Cough—Epirubicin—hematologic cancer	3.11e-05	5.28e-05	CcSEcCtD
Methylphenidate—Anaphylactic shock—Methotrexate—hematologic cancer	3.11e-05	5.27e-05	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—hematologic cancer	3.11e-05	5.27e-05	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—hematologic cancer	3.09e-05	5.24e-05	CcSEcCtD
Methylphenidate—Infection—Methotrexate—hematologic cancer	3.09e-05	5.24e-05	CcSEcCtD
Methylphenidate—Nausea—Etoposide—hematologic cancer	3.08e-05	5.23e-05	CcSEcCtD
Methylphenidate—Hypertension—Epirubicin—hematologic cancer	3.08e-05	5.22e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Prednisone—hematologic cancer	3.06e-05	5.2e-05	CcSEcCtD
Methylphenidate—Asthenia—Dexamethasone—hematologic cancer	3.06e-05	5.2e-05	CcSEcCtD
Methylphenidate—Asthenia—Betamethasone—hematologic cancer	3.06e-05	5.2e-05	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—hematologic cancer	3.06e-05	5.19e-05	CcSEcCtD
Methylphenidate—Nervous system disorder—Methotrexate—hematologic cancer	3.05e-05	5.17e-05	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—hematologic cancer	3.05e-05	5.17e-05	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—hematologic cancer	3.04e-05	5.16e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Prednisone—hematologic cancer	3.04e-05	5.16e-05	CcSEcCtD
Methylphenidate—Nausea—Prednisolone—hematologic cancer	3.04e-05	5.16e-05	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—hematologic cancer	3.03e-05	5.15e-05	CcSEcCtD
Methylphenidate—Chest pain—Epirubicin—hematologic cancer	3.03e-05	5.15e-05	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—hematologic cancer	3.03e-05	5.15e-05	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—hematologic cancer	3.03e-05	5.14e-05	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—hematologic cancer	3.02e-05	5.13e-05	CcSEcCtD
Methylphenidate—Pruritus—Dexamethasone—hematologic cancer	3.02e-05	5.12e-05	CcSEcCtD
Methylphenidate—Pruritus—Betamethasone—hematologic cancer	3.02e-05	5.12e-05	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—hematologic cancer	3.02e-05	5.12e-05	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.01e-05	5.11e-05	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—hematologic cancer	3e-05	5.1e-05	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—hematologic cancer	3e-05	5.08e-05	CcSEcCtD
Methylphenidate—Vomiting—Triamcinolone—hematologic cancer	2.99e-05	5.08e-05	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—hematologic cancer	2.97e-05	5.04e-05	CcSEcCtD
Methylphenidate—Rash—Triamcinolone—hematologic cancer	2.97e-05	5.03e-05	CcSEcCtD
Methylphenidate—Dry mouth—Epirubicin—hematologic cancer	2.97e-05	5.03e-05	CcSEcCtD
Methylphenidate—Dermatitis—Triamcinolone—hematologic cancer	2.96e-05	5.03e-05	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—hematologic cancer	2.96e-05	5.03e-05	CcSEcCtD
Methylphenidate—Anorexia—Methotrexate—hematologic cancer	2.96e-05	5.03e-05	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—hematologic cancer	2.96e-05	5.02e-05	CcSEcCtD
Methylphenidate—Urticaria—Prednisone—hematologic cancer	2.95e-05	5.01e-05	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—hematologic cancer	2.95e-05	5.01e-05	CcSEcCtD
Methylphenidate—Headache—Triamcinolone—hematologic cancer	2.95e-05	5e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Prednisone—hematologic cancer	2.94e-05	4.99e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Prednisone—hematologic cancer	2.94e-05	4.99e-05	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—hematologic cancer	2.93e-05	4.97e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Betamethasone—hematologic cancer	2.92e-05	4.96e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Dexamethasone—hematologic cancer	2.92e-05	4.96e-05	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—hematologic cancer	2.91e-05	4.94e-05	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—hematologic cancer	2.91e-05	4.93e-05	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—hematologic cancer	2.91e-05	4.93e-05	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—hematologic cancer	2.9e-05	4.92e-05	CcSEcCtD
Methylphenidate—Infection—Epirubicin—hematologic cancer	2.89e-05	4.9e-05	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—hematologic cancer	2.88e-05	4.88e-05	CcSEcCtD
Methylphenidate—Shock—Epirubicin—hematologic cancer	2.86e-05	4.85e-05	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—hematologic cancer	2.86e-05	4.85e-05	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—hematologic cancer	2.85e-05	4.84e-05	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—hematologic cancer	2.85e-05	4.83e-05	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—hematologic cancer	2.85e-05	4.83e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—ASNS—hematologic cancer	2.84e-05	0.000569	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—DCK—hematologic cancer	2.84e-05	0.000569	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—B3GAT1—hematologic cancer	2.84e-05	0.000569	CbGpPWpGaD
Methylphenidate—Tachycardia—Epirubicin—hematologic cancer	2.84e-05	4.82e-05	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.83e-05	4.8e-05	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—hematologic cancer	2.82e-05	4.79e-05	CcSEcCtD
Methylphenidate—Dizziness—Betamethasone—hematologic cancer	2.82e-05	4.79e-05	CcSEcCtD
Methylphenidate—Dizziness—Dexamethasone—hematologic cancer	2.82e-05	4.79e-05	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—hematologic cancer	2.81e-05	4.77e-05	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—hematologic cancer	2.81e-05	4.77e-05	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—hematologic cancer	2.81e-05	4.76e-05	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—hematologic cancer	2.81e-05	4.76e-05	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—hematologic cancer	2.81e-05	4.76e-05	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—hematologic cancer	2.8e-05	4.75e-05	CcSEcCtD
Methylphenidate—Nausea—Triamcinolone—hematologic cancer	2.79e-05	4.74e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Methotrexate—hematologic cancer	2.79e-05	4.73e-05	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.79e-05	4.73e-05	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—hematologic cancer	2.77e-05	4.7e-05	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—hematologic cancer	2.77e-05	4.7e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Methotrexate—hematologic cancer	2.77e-05	4.7e-05	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—hematologic cancer	2.76e-05	4.69e-05	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—hematologic cancer	2.74e-05	4.66e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Prednisone—hematologic cancer	2.74e-05	4.65e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Methotrexate—hematologic cancer	2.73e-05	4.64e-05	CcSEcCtD
Methylphenidate—Vomiting—Betamethasone—hematologic cancer	2.71e-05	4.61e-05	CcSEcCtD
Methylphenidate—Vomiting—Dexamethasone—hematologic cancer	2.71e-05	4.61e-05	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—hematologic cancer	2.71e-05	4.6e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Methotrexate—hematologic cancer	2.7e-05	4.58e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—HDC—hematologic cancer	2.69e-05	0.000539	CbGpPWpGaD
Methylphenidate—Rash—Dexamethasone—hematologic cancer	2.69e-05	4.57e-05	CcSEcCtD
Methylphenidate—Rash—Betamethasone—hematologic cancer	2.69e-05	4.57e-05	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—hematologic cancer	2.69e-05	4.56e-05	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—hematologic cancer	2.69e-05	4.56e-05	CcSEcCtD
Methylphenidate—Dermatitis—Dexamethasone—hematologic cancer	2.69e-05	4.56e-05	CcSEcCtD
Methylphenidate—Dermatitis—Betamethasone—hematologic cancer	2.69e-05	4.56e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.68e-05	4.55e-05	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—hematologic cancer	2.68e-05	4.55e-05	CcSEcCtD
Methylphenidate—Headache—Betamethasone—hematologic cancer	2.67e-05	4.54e-05	CcSEcCtD
Methylphenidate—Headache—Dexamethasone—hematologic cancer	2.67e-05	4.54e-05	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—hematologic cancer	2.67e-05	4.54e-05	CcSEcCtD
Methylphenidate—Asthenia—Prednisone—hematologic cancer	2.67e-05	4.53e-05	CcSEcCtD
Methylphenidate—Pain—Methotrexate—hematologic cancer	2.66e-05	4.51e-05	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.65e-05	4.49e-05	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—hematologic cancer	2.65e-05	4.49e-05	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—hematologic cancer	2.64e-05	4.48e-05	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—hematologic cancer	2.63e-05	4.47e-05	CcSEcCtD
Methylphenidate—Pruritus—Prednisone—hematologic cancer	2.63e-05	4.46e-05	CcSEcCtD
Methylphenidate—Insomnia—Epirubicin—hematologic cancer	2.63e-05	4.46e-05	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—hematologic cancer	2.63e-05	4.46e-05	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—hematologic cancer	2.61e-05	4.43e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—hematologic cancer	2.61e-05	4.43e-05	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—hematologic cancer	2.6e-05	4.41e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Epirubicin—hematologic cancer	2.59e-05	4.4e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—HRAS—hematologic cancer	2.59e-05	0.000518	CbGpPWpGaD
Methylphenidate—Somnolence—Epirubicin—hematologic cancer	2.58e-05	4.39e-05	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.58e-05	0.000517	CbGpPWpGaD
Methylphenidate—Anorexia—Doxorubicin—hematologic cancer	2.56e-05	4.35e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—hematologic cancer	2.56e-05	4.34e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—hematologic cancer	2.56e-05	4.34e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Prednisone—hematologic cancer	2.54e-05	4.32e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Methotrexate—hematologic cancer	2.54e-05	4.31e-05	CcSEcCtD
Methylphenidate—Nausea—Betamethasone—hematologic cancer	2.54e-05	4.3e-05	CcSEcCtD
Methylphenidate—Nausea—Dexamethasone—hematologic cancer	2.54e-05	4.3e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Epirubicin—hematologic cancer	2.53e-05	4.29e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.51e-05	4.26e-05	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—hematologic cancer	2.51e-05	4.25e-05	CcSEcCtD
Methylphenidate—Pain—Epirubicin—hematologic cancer	2.49e-05	4.22e-05	CcSEcCtD
Methylphenidate—Constipation—Epirubicin—hematologic cancer	2.49e-05	4.22e-05	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—hematologic cancer	2.47e-05	4.19e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—CDA—hematologic cancer	2.46e-05	0.000493	CbGpPWpGaD
Methylphenidate—Dizziness—Prednisone—hematologic cancer	2.46e-05	4.17e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Methotrexate—hematologic cancer	2.46e-05	4.17e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—hematologic cancer	2.46e-05	4.17e-05	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.45e-05	4.16e-05	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—hematologic cancer	2.43e-05	4.13e-05	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ALB—hematologic cancer	2.42e-05	0.000484	CbGpPWpGaD
Methylphenidate—Paraesthesia—Doxorubicin—hematologic cancer	2.42e-05	4.1e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—hematologic cancer	2.4e-05	4.07e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—hematologic cancer	2.4e-05	4.07e-05	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—hematologic cancer	2.39e-05	4.06e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—hematologic cancer	2.38e-05	4.03e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—PC—hematologic cancer	2.37e-05	0.000475	CbGpPWpGaD
Methylphenidate—Dyspepsia—Doxorubicin—hematologic cancer	2.37e-05	4.02e-05	CcSEcCtD
Methylphenidate—Vomiting—Prednisone—hematologic cancer	2.36e-05	4.01e-05	CcSEcCtD
Methylphenidate—Rash—Prednisone—hematologic cancer	2.34e-05	3.98e-05	CcSEcCtD
Methylphenidate—Dermatitis—Prednisone—hematologic cancer	2.34e-05	3.97e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—hematologic cancer	2.34e-05	3.97e-05	CcSEcCtD
Methylphenidate—Headache—Prednisone—hematologic cancer	2.33e-05	3.95e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.32e-05	3.94e-05	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—hematologic cancer	2.32e-05	3.94e-05	CcSEcCtD
Methylphenidate—Urticaria—Epirubicin—hematologic cancer	2.31e-05	3.92e-05	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—hematologic cancer	2.3e-05	3.9e-05	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—hematologic cancer	2.3e-05	3.9e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—hematologic cancer	2.3e-05	3.9e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Epirubicin—hematologic cancer	2.3e-05	3.9e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—GBA—hematologic cancer	2.29e-05	0.000459	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC35B2—hematologic cancer	2.29e-05	0.000459	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Methotrexate—hematologic cancer	2.29e-05	3.88e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.29e-05	0.000458	CbGpPWpGaD
Methylphenidate—Asthenia—Methotrexate—hematologic cancer	2.23e-05	3.78e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Doxorubicin—hematologic cancer	2.22e-05	3.76e-05	CcSEcCtD
Methylphenidate—Nausea—Prednisone—hematologic cancer	2.21e-05	3.75e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.2e-05	3.73e-05	CcSEcCtD
Methylphenidate—Pruritus—Methotrexate—hematologic cancer	2.2e-05	3.73e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Epirubicin—hematologic cancer	2.14e-05	3.63e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ALB—hematologic cancer	2.14e-05	0.000429	CbGpPWpGaD
Methylphenidate—Urticaria—Doxorubicin—hematologic cancer	2.14e-05	3.63e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—hematologic cancer	2.13e-05	3.61e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—hematologic cancer	2.13e-05	3.61e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Methotrexate—hematologic cancer	2.13e-05	3.61e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—MTAP—hematologic cancer	2.09e-05	0.000419	CbGpPWpGaD
Methylphenidate—Asthenia—Epirubicin—hematologic cancer	2.09e-05	3.54e-05	CcSEcCtD
Methylphenidate—Pruritus—Epirubicin—hematologic cancer	2.06e-05	3.49e-05	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—hematologic cancer	2.05e-05	3.49e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Epirubicin—hematologic cancer	1.99e-05	3.38e-05	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—HRAS—hematologic cancer	1.98e-05	0.000397	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Doxorubicin—hematologic cancer	1.98e-05	3.36e-05	CcSEcCtD
Methylphenidate—Vomiting—Methotrexate—hematologic cancer	1.98e-05	3.35e-05	CcSEcCtD
Methylphenidate—Rash—Methotrexate—hematologic cancer	1.96e-05	3.32e-05	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—hematologic cancer	1.96e-05	3.32e-05	CcSEcCtD
Methylphenidate—Headache—Methotrexate—hematologic cancer	1.95e-05	3.3e-05	CcSEcCtD
Methylphenidate—Asthenia—Doxorubicin—hematologic cancer	1.93e-05	3.28e-05	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—hematologic cancer	1.92e-05	3.26e-05	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—hematologic cancer	1.9e-05	3.23e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—FHL2—hematologic cancer	1.87e-05	0.000374	CbGpPWpGaD
Methylphenidate—Vomiting—Epirubicin—hematologic cancer	1.85e-05	3.14e-05	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—hematologic cancer	1.85e-05	3.13e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—hematologic cancer	1.84e-05	3.12e-05	CcSEcCtD
Methylphenidate—Rash—Epirubicin—hematologic cancer	1.83e-05	3.11e-05	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—hematologic cancer	1.83e-05	3.11e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—AGRN—hematologic cancer	1.83e-05	0.000367	CbGpPWpGaD
Methylphenidate—Headache—Epirubicin—hematologic cancer	1.82e-05	3.09e-05	CcSEcCtD
Methylphenidate—Dizziness—Doxorubicin—hematologic cancer	1.78e-05	3.02e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—IDH2—hematologic cancer	1.74e-05	0.000348	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMMR—hematologic cancer	1.74e-05	0.000348	CbGpPWpGaD
Methylphenidate—Nausea—Epirubicin—hematologic cancer	1.73e-05	2.93e-05	CcSEcCtD
Methylphenidate—Vomiting—Doxorubicin—hematologic cancer	1.71e-05	2.9e-05	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—hematologic cancer	1.7e-05	2.88e-05	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—hematologic cancer	1.69e-05	2.88e-05	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—hematologic cancer	1.69e-05	2.86e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—ARNTL—hematologic cancer	1.63e-05	0.000327	CbGpPWpGaD
Methylphenidate—Nausea—Doxorubicin—hematologic cancer	1.6e-05	2.71e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—CA9—hematologic cancer	1.59e-05	0.000318	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACP5—hematologic cancer	1.59e-05	0.000318	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOR2—hematologic cancer	1.57e-05	0.000314	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—IDH1—hematologic cancer	1.49e-05	0.000299	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTO1—hematologic cancer	1.48e-05	0.000295	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCC3—hematologic cancer	1.48e-05	0.000295	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TXN—hematologic cancer	1.48e-05	0.000295	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SPHK1—hematologic cancer	1.44e-05	0.000289	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGT1A1—hematologic cancer	1.39e-05	0.000278	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC22A1—hematologic cancer	1.35e-05	0.00027	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CRABP1—hematologic cancer	1.35e-05	0.00027	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALOX5—hematologic cancer	1.32e-05	0.000263	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NUP98—hematologic cancer	1.27e-05	0.000255	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADCY7—hematologic cancer	1.24e-05	0.000248	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOA3—hematologic cancer	1.24e-05	0.000248	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NUP214—hematologic cancer	1.23e-05	0.000246	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCG2—hematologic cancer	1.2e-05	0.000241	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTR—hematologic cancer	1.2e-05	0.000241	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENO2—hematologic cancer	1.18e-05	0.000236	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—hematologic cancer	1.14e-05	0.000229	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SDC1—hematologic cancer	1.12e-05	0.000224	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NQO1—hematologic cancer	9.51e-06	0.00019	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CD44—hematologic cancer	9.51e-06	0.00019	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYCS—hematologic cancer	9e-06	0.00018	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	8.94e-06	0.000179	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—hematologic cancer	7.93e-06	0.000159	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCB1—hematologic cancer	7.51e-06	0.00015	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—hematologic cancer	7.29e-06	0.000146	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOR1—hematologic cancer	7.29e-06	0.000146	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTHFR—hematologic cancer	6.44e-06	0.000129	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CG—hematologic cancer	5.41e-06	0.000108	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CREBBP—hematologic cancer	5.02e-06	0.0001	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CD—hematologic cancer	4.76e-06	9.53e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALB—hematologic cancer	4.7e-06	9.4e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3R1—hematologic cancer	4.49e-06	9e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CB—hematologic cancer	4.15e-06	8.3e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—hematologic cancer	3.58e-06	7.18e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EP300—hematologic cancer	3.42e-06	6.84e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.53e-06	5.06e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—hematologic cancer	2.06e-06	4.14e-05	CbGpPWpGaD
